Evaluation of the effects of erythro-9(2-hydroxy-3-nonyl) adenine (EHNA) on HIV-1 production in vitro

Biochem Biophys Res Commun. 1989 Oct 16;164(1):345-50. doi: 10.1016/0006-291x(89)91724-5.

Abstract

Effects of erythro-9(2-hydroxy-3-nonyl) adenine (EHNA), an inhibitor of the common Adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4.), on HIV-1 production was evaluated in vitro. Reverse transcriptase (RT) activity in the supernatant was inhibited by nearly 50% in EHNA-treated HIV-1 infected H9 cells, when compared with untreated but infected H9 cells. There was also a significant decrease in cell viability, but this was reversed following the addition of deoxycytidine (dC) to these cultures. The combined treatment was also effective in suppressing HIV-1 release from HIV-1-infected U937 cells. This combined EHNA plus dC treatment had no effect on RT activity in the cell lysates, suggesting that the inhibition of HIV-1 production may be due to the disturbance of virus release from infected cells.

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / pharmacology
  • Adenosine Deaminase Inhibitors
  • Antiviral Agents / pharmacology*
  • Cell Line
  • Deoxycytidine / pharmacology
  • Drug Synergism
  • Flow Cytometry
  • HIV Envelope Protein gp120 / metabolism
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • RNA-Directed DNA Polymerase / metabolism
  • Virus Replication / drug effects*

Substances

  • Adenosine Deaminase Inhibitors
  • Antiviral Agents
  • HIV Envelope Protein gp120
  • Deoxycytidine
  • 9-(2-hydroxy-3-nonyl)adenine
  • RNA-Directed DNA Polymerase
  • Adenine